Zydus Cadila gets approval from USFDA to market Palbociclib Capsules

24 Sep 2020 Evaluate

Zydus Cadila has received tentative approval from the US Food & Drug Administration ( USFDA) to market Palbociclib Capsules, (US RLD: Ibrance Capsules) in the strengths of 75 mg, 100 mg, and 125 mg. Palbociclib is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 302 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

1082.55 26.55 (2.51%)
10-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1510.00
Dr. Reddys Lab 6089.30
Cipla 1533.80
Zydus Lifesciences 1082.55
Lupin 1630.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.